1314241-10-5
1314241-10-5
Chemical Structure
Orticumab
Synonym(s): MLDL1278A
- CAS No.: 1314241-10-5
- Formula:N/A
- Molecular Weight:(143.68 kDa)
IUPAC Name: ethyl 4-hydroxyisoxazole-3-carboxylate
SMILES: [Orticumab]
Biological Activity: Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Orticumab | ≥99.0% | Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. [Content Brief]
- [2]. Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.
Keywords
